*Advance our knowledge of the basic immunology of inflammation, autoimmunity, cancer, transplantation and infection and to translate this new knowledge to novel strategies for diagnosis, prevention and therapeutic intervention.
*Foster collaborations and further strengthen interactions among the Penn community of immunologists.
Spotlights on IFI
David Weiner and Lab Recognized for Vaccine ResearchDavid Weiner, PhD and his research team were awarded the 2015 Vaccine Industry Excellence Award at a recent meeting of the World Vaccine Congress.
The Wistar Institute Training Program Selects 2014 Memorial Fellowship Award Winner
Susanne Linderman has been chosen by The Wistar Institute’s training committee as the recipient of the 2014 Monica H. M. Shander Memorial Fellowship Award for her work on how previous influenza exposures affect specificities of influenza antibody responses and, therefore, vaccination success. Susanne is currently a Ph.D. candidate (expected graduation September 2015) in the Immunology Graduate Group in the University of Pennsylvania's Biomedical Graduate Studies Program. She graduated with a B.S. in biophysics from Brigham Young University in 2010, and the following year she joined the laboratory of Scott E. Hensley, Ph.D., an assistant professor and member of Wistar’s Vaccine Center. Read More
Immunology: Oral Solutions
Dr. Henry Daniell is featured in Nature regarding his work on pills made from lettuce leaves that could help to prevent one of the most serious complications of haemophilia treatment. Click here to read more
HIV Helped Utah Man Battle Cancer: How Disabled HIV Turns T-Cells Into "Serial Killers" of Turmos
Click this link to read more about this amazing story.
Immunomedics Announce Orphan Drug Designation for Veltuzumab for the Treatment of Pemphigus
Dr. Aimee Payne specializes in a rare and life threatening disease known as pemphigus vulgaris. Dr. Payne recently wrote and received approval from the FDA for an investigational new drug protocol to treat a refractory patient with a novel anti CD20 monoclonal antibody known as veltuzumab. The patient's disease went into complete remission, and based on Dr. Payne's work, Immunomedics applied for and just received orphan drug status for veltuzumab in PV. They are now in the process of planning a clinical trial to gain FDA approval.
Click here to read more this discovery